In its first quarter on the market, Roche's MS drug, Ocrevus, has generated $200 million. This has caught the market by surprise given the fact that Roche priced the drug at a 25% discount compared to other MS drugs on the market.
Ocrevus is used for the treatment of two forms of multiple sclerosis. The figures are so good that Roche had decided to raise its 2017 forecast.
Click here to view this entire article.